Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

PubWeight™: 3.28‹?› | Rank: Top 1%

🔗 View Article (PMID 11181775)

Published in J Natl Cancer Inst on February 21, 2001

Authors

C D Harro1, Y Y Pang, R B Roden, A Hildesheim, Z Wang, M J Reynolds, T C Mast, R Robinson, B R Murphy, R A Karron, J Dillner, J T Schiller, D R Lowy

Author Affiliations

1: Center for Immunization Research, Department of International Medicine, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD, USA.

Articles citing this

The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73

Human papillomavirus and cervical cancer. Clin Microbiol Rev (2003) 3.90

Maturation of papillomavirus capsids. J Virol (2005) 3.18

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71

Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36

In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe (2010) 2.24

How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23

Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis (2003) 2.06

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95

Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol (2003) 1.82

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 1.75

Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst (2001) 1.65

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63

Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58

HPV - immune response to infection and vaccination. Infect Agent Cancer (2010) 1.48

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48

Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48

Interactions between papillomavirus L1 and L2 capsid proteins. J Virol (2003) 1.41

Progress on new vaccine strategies against chronic viral infections. J Clin Invest (2004) 1.38

Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol (2005) 1.37

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35

Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev (2012) 1.33

Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27

Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin Diagn Lab Immunol (2004) 1.27

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25

Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol (2007) 1.23

Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood (2006) 1.21

Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol (2006) 1.17

Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology (2007) 1.16

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol (2003) 1.12

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol (2003) 1.11

Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol (2002) 1.08

Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol (2006) 1.06

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05

Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J Clin Microbiol (2007) 1.02

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine (2014) 1.02

A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine (2013) 1.02

Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology (2009) 1.01

Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00

Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98

Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines (2005) 0.95

Virus-like particles production in green plants. Methods (2006) 0.94

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine (2010) 0.94

Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol (2009) 0.93

Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One (2013) 0.92

Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine (2007) 0.92

Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles. Clin Vaccine Immunol (2007) 0.92

Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92

Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol (2010) 0.92

Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol (2006) 0.90

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virol (2009) 0.89

Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium. Infect Immun (2004) 0.89

Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (2005) 0.88

Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines (2013) 0.88

A Virus-based Vaccine May Prevent Cervical Cancer. Curr Infect Dis Rep (2005) 0.88

Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol (2007) 0.87

Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. BMC Infect Dis (2010) 0.86

Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86

Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol (2004) 0.85

Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. J Virol (2004) 0.85

Does human papillomavirus cause pterygium? Br J Ophthalmol (2003) 0.84

Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) (2014) 0.84

Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc Natl Acad Sci U S A (2005) 0.84

Reducing the health burden of HPV infection through vaccination. Infect Dis Obstet Gynecol (2006) 0.83

Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol (2014) 0.82

HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest (2016) 0.81

Knowledge about HPV, relation between HPV and cervix cancer and acceptance of HPV vaccine in women in eastern region of Turkey. J Gynecol Oncol (2013) 0.81

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One (2014) 0.81

Prophylactic HPV vaccines. J Clin Pathol (2007) 0.80

Dendritic cells and vaccine design for sexually-transmitted diseases. Microb Pathog (2012) 0.80

Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. FASEB J (2012) 0.79

Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol (2002) 0.79

Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev (2011) 0.79

Human Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea. J Cancer Prev (2016) 0.78

Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine. Clin Vaccine Immunol (2014) 0.78

Induction of immune responses against human papillomaviruses by hypervariable epitope constructs. Immunology (2004) 0.77

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum Vaccin Immunother (2014) 0.77

Cancer prevention in HIV-infected populations. Semin Oncol (2015) 0.77

Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother (2015) 0.76

Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus. Viruses (2016) 0.75

Predisposition to Cervical Atypia in Systemic Lupus Erythematosus: A Clinical and Cytopathological Study. Autoimmune Dis (2015) 0.75

Complete Genome Sequence of the Autographa californica Multiple Nucleopolyhedrovirus Strain E2. Genome Announc (2014) 0.75

Detection of Human Papillomavirus 16-Specific IgG and IgM Antibodies in Patient Sera: A Potential Indicator of Oral Squamous Cell Carcinoma Risk Factor. Int J Med Sci (2016) 0.75

Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies. Curr Protoc Microbiol (2015) 0.75

Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative. J Transl Med (2015) 0.75

Immune response modulation by recombinant peptides expressed in virus-like particles. Clin Exp Immunol (2002) 0.75

Articles by these authors

The sequence of the human genome. Science (2001) 101.55

The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res (2005) 12.94

Studies in the biochemistry of micro-organisms: Helminthosporin and hydroxyisohelminthosporin, metabolic products of the plant pathogen Helminthosporium gramineum Rabenhorst. Biochem J (1933) 12.74

Mechanism of activation of a human oncogene. Nature (1982) 12.09

Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50

A survey of anthocyanins. I. Biochem J (1931) 10.49

A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol (1993) 10.22

Mouse cells transformed by bovine papillomavirus contain only extrachromosomal viral DNA sequences. Proc Natl Acad Sci U S A (1981) 9.27

Murine leukemia virus: high-frequency activation in vitro by 5-iododeoxyuridine and 5-bromodeoxyuridine. Science (1971) 8.78

The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38

Cereal genome evolution. Grasses, line up and form a circle. Curr Biol (1995) 8.33

Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell (2001) 8.09

Evidence based policymaking. BMJ (1995) 8.08

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet (2014) 8.04

Helper-independent transformation by unintegrated Harvey sarcoma virus DNA. J Virol (1978) 7.75

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72

Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 7.26

A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14

In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA. Nature (1980) 6.67

HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60

Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A (1995) 6.51

The Y-family of DNA polymerases. Mol Cell (2001) 6.49

Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33

Studies in the biochemistry of micro-organisms: Cynodontin (1:4:5:8-tetrahydroxy-2-methylanthraquinone), a metabolic product of Helminthosporium cynodontis Marignoni and Helminthosporium euchlaenae Zimmermann. Biochem J (1933) 6.31

Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99

Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1984) 5.88

Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature (1987) 5.61

Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51

Genetic diversity and disease control in rice. Nature (2000) 5.34

Cellular origin and role of mink cell focus-forming viruses in murine thymic lymphomas. Nature (1982) 5.23

Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12

Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 5.08

Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst (1993) 5.07

Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus. J Virol (1980) 4.91

Molecular cloning of infectious integrated murine leukemia virus DNA from infected mouse cells. Proc Natl Acad Sci U S A (1980) 4.71

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69

Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63

HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA (2000) 4.62

Origin of mink cytopathic focus-forming (MCF) viruses:comparison with ecotropic and xenotropic murine leukemia virus genomes. Virology (1981) 4.62

An internal control for routine diagnostic PCR: design, properties, and effect on clinical performance. J Clin Microbiol (1998) 4.58

Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science (1988) 4.58

Virus-specific transcription in bovine papillomavirus-transformed mouse cells. Virology (1982) 4.52

Qualitative and quantitative studies of AKR-type murine leukemia virus sequences in mouse DNA. Cold Spring Harb Symp Quant Biol (1975) 4.49

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol (1973) 4.47

The p21 ras C-terminus is required for transformation and membrane association. Nature (1984) 4.43

Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J (1984) 4.28

A survey of anthocyanins. IV. Biochem J (1934) 4.25

Genomes of murine leukemia viruses isolated from wild mice. J Virol (1981) 4.24

Structure of endogenous murine leukemia virus DNA in mouse genomes. Proc Natl Acad Sci U S A (1980) 4.24

Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest (2000) 4.16

Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14

Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06

E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04

A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95

Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93

Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90

Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis (1973) 3.89

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87

Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation (2000) 3.82

Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst (2000) 3.81

The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys. J Virol (1987) 3.76

Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67

Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica (1997) 3.67

In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66

Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol (1998) 3.65

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64

Virus infection of murine teratocarcinoma stem cell lines. Cell (1977) 3.54

Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53

Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med (1972) 3.51

Definitive evidence that the murine C-type virus inducing locus Akv-1 is viral genetic material. Proc Natl Acad Sci U S A (1975) 3.51

Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A (1997) 3.49

Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48

Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46

Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33

Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30

Isolation and Characterization of an Anaerobic, Cellulolytic Bacterium, Clostridium cellulovorans sp. nov. Appl Environ Microbiol (1984) 3.28

Nucleoprotein and membrane protein genes are associated with restriction of replication of influenza A/Mallard/NY/78 virus and its reassortants in squirrel monkey respiratory tract. J Virol (1985) 3.27

Characterization of a human colon/lung carcinoma oncogene. Nature (1983) 3.26

Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun (1982) 3.22

Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science (1985) 3.21

The transforming function of bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1983) 3.19

Translation of open reading frame E5 of bovine papillomavirus is required for its transforming activity. Proc Natl Acad Sci U S A (1986) 3.17

Studies in the biochemistry of micro-organisms: (a) On the production of hydroxyanthraquinones by species of Helminthosporium. (b) Isolation of tritisporin, a new metabolic product of Helminthosporium tritici-vulgaris Nisikado. (c) The molecular constitution of catenarin. Biochem J (1934) 3.12

Regulation of imprinted X-chromosome inactivation in mice by Tsix. Development (2001) 3.12

JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut (2008) 3.06

Integrated human genome-wide maps constructed using the CEPH reference panel. Nat Genet (1994) 3.06